Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:33:04.639Z.
Calculation as of: 2026-10-06T17:33:04.639Z.
Quote observation: 2026-10-06T17:30:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2ce25f957fe83095360266a8eba44a0c9f304ca71e6017df3a9cc6b1c586d311
PE RATIO
N/A
Market Cap
$403.58M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$406.94M
PE Ratio
N/A
TTM Avg
22.42
3Y Avg
51.74
5Y Avg
51.74
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) | $391.58M | N/A | N/A | N/A | N/A |
| REGENXBIO Inc. (RGNX)vs › | $386.95M | N/A | 13.34 | 13.34 | 21.63 |
| Orthofix Medical Inc. (OFIX)vs › | $385.22M | N/A | 157.27 | 122.07 | 183.95 |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $403.58M | N/A | N/A | N/A | N/A |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $379.71M | N/A | N/A | N/A | N/A |
| Carlsmed, Inc. (CARL)vs › | $405.74M | N/A | N/A | N/A | N/A |
| Neurogene Inc. (NGNE)vs › | $406.04M | N/A | 21.17 | 21.07 | 21.07 |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $406.94M | N/A | 22.42 | 51.74 | 51.74 |
| Rezolute, Inc. (RZLT)vs › | $407.80M | N/A | N/A | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $372.63M | N/A | 20.42 | 20.42 | 20.42 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$9.23
Forward EPS (Est.)
$-4.94
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
